Table 4.
Signaling pathway analysis of the genetic interaction network associated with carfilzomib resistance in KMS-11 cell line in terms of GO
| Pathway ID | Signaling pathway | Observed gene count | FDR |
|---|---|---|---|
| 4060 | Cytokine–cytokine receptor interaction | 13 | 1.28E-07 |
| 4140 | Regulation of autophagy | 6 | 4.82E-06 |
| 280 | Valine, leucine and isoleucine degradation | 6 | 6.81E-06 |
| 1212 | Fatty acid metabolism | 6 | 8.74E-06 |
| 5215 | Prostate cancer | 7 | 1.12E-05 |
| 5214 | Glioma | 6 | 2.51E-05 |
| 71 | Fatty acid degradation | 5 | 8.59E-05 |
| 900 | Terpenoid backbone biosynthesis | 4 | 0.000108 |
| 72 | Synthesis and degradation of ketone bodies | 3 | 0.000297 |
| 270 | Cysteine and methionine metabolism | 4 | 0.000733 |
| 5200 | Pathways in cancer | 9 | 0.000733 |
| 1100 | Metabolic pathways | 17 | 0.00106 |
| 4962 | Vasopressin-regulated water reabsorption | 4 | 0.00139 |
| 5206 | MicroRNAs in cancer | 6 | 0.0015 |
| 5212 | Pancreatic cancer | 4 | 0.00433 |
| 650 | Butanoate metabolism | 3 | 0.00487 |
| 5218 | Melanoma | 4 | 0.00615 |
| 4012 | ErbB signaling pathway | 4 | 0.0111 |
| 4540 | Gap junction | 4 | 0.0111 |
Abbreviations: FDR, false discovery rate; GO, Gene Ontology.